Full Press Release Details
Lantern Pharma Reports
First Quarter 2021 Financial Results and Operational Highlights
DALLAS, TX - May 3, 2021 - Lantern Pharma Inc. (NASDAQ: LTRN),
a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform
to transform oncology drug discovery and development today announced financial results for the first quarter ended March 31, 2021.
"We are very pleased with our continued rapid progress in expanding
and advancing our pipeline of targeted cancer drug candidates and are on pace to launch the Phase 2 trial of LP-300 in non-small cell
lung cancer among non-smokers in the third quarter of this year," stated Panna Sharma, President and CEO of Lantern Pharma. "During
the first quarter, we dramatically accelerated the pace with which we gather, curate, tag and assemble biologically relevant data for
our RADR A.I. platform. Our RADR A.I. platform now exceeds 4.6 billion datapoints, representing a nearly
16-fold increase in the number of datapoints since our IPO in June 2020. RADR grew by approximately 1 billion datapoints
per month during the first quarter of 2021. The size and scope of our RADR A.I. platform is opening up new insights and
areas of opportunity for the discovery of additional indications for our existing drug candidates, as well as the identification of entirely
new drug candidates and new therapeutic indications for existing molecules in the fight against cancer."
"Perhaps most exciting, as our RADR A.I. platform
grows, potential partnerships with biopharma companies are now even more clearly in our sights," continued Sharma. "Earlier
today, we announced that we have entered into an equity-based collaboration with Actuate Therapeutics to apply the remarkable power of
RADR to better understand the mechanism of action of Actuate's 9-ING-41 drug candidate and utilize these insights
to advance a biomarker signature of response and a biomarker guided development strategy. We are excited about the opportunity to continue
to build additional value-driven partnerships in the quarters ahead."
The collaboration will focus on leveraging the RADR
machine learning technology, large-scale oncology datasets, and the A.I. platform to accelerate key aspects of Actuate's 9-ING-41 drug
candidate, a best-in-class GSK-3 inhibitor in active development in multiple Phase 2 clinical trials, including for pancreatic
cancer. The collaboration is expected to start immediately and will potentially generate novel intellectual property that will be jointly
owned by the companies. Lantern will receive upfront equity in Actuate Therapeutics subject to meeting certain conditions of the collaboration,
as well as development milestones in the form of additional equity if results from the collaboration are utilized in future development
Lantern is developing four drug candidates and an ADC program across
seven disclosed targets, including:
First Quarter 2021 Financial Highlights
Mr. Sharma concluded, "We will continue to aggressively advance
our portfolio, both clinically and in new preclinical indications, and continue to leverage our A.I. platform to uncover new rescue or
repurposing opportunities on our own or with partners. Our team is committed to building Lantern into a best-of-breed biopharma company
that transforms the cost, pace and risk of oncology drug development by leveraging insight from our RADR A.I. platform
with the experience and expertise of our cancer-focused research team and a roster of collaborations with world-renowned cancer research
institutions. Our financial position has never been stronger and our portfolio of targeted oncology drug candidates is positioned to deliver
significant ongoing value for shareholders."
Lantern will host a conference call and webcast today, Monday, May
Toll-free US and Canada: 800 791 4813
- conference ID 97381
US and Canada callers one touch dial:
+1.800.791.4813,,97381#
International: 785 424 1102
- conference ID 97381
Replay Number: 1-800-839 8389, no
passcode. Available through 11:59 pm ET on June 3, 2021.
Live webcast will be available at: https://www.webcaster4.com/Webcast/Page/2460/41104
The webcast will be archived on https://ir.lanternpharma.com
through 11:59 pm ET on June 3, 2021.
Director, Investor Relations
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical
company leveraging its proprietary RADR A.I. platform and machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates
and an ADC program across seven disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic
profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential
to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial
performance; the potential advantages of our RADR platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody
drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development
program; our research and development efforts of our internal drug discovery programs and the utilization of our
RADR platform to streamline the drug development process; our intention to leverage artificial intelligence, machine
learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to
identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential
market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not
statements of historical fact (including, without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict,"
"project," "target," "objective," "aim," "should," "will,"
"would," or the negative of these words or other similar expressions) should be considered forward-looking statements.
There are a number of important factors that could cause our actual results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that none of our product candidates has
received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or
obtain marketing approval for our product candidates; (iii) the risk that no drug product based on our proprietary RADR A.I.
platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (iv) those other factors
set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the
Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31,
2020 under the investor SEC filings tab of our website at www.lanternpharma.com
or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking
statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking
statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking
statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim
any obligation to update any forward-looking statements to conform the statement to actual results or changes in our
Lantern Pharma Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| (Unaudited) | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | 81,373,725 | $ | 19,229,232 | ||||
| Prepaid expenses and other current assets | 1,110,770 | 1,007,690 | ||||||
| Total current assets | 82,484,495 | 20,236,922 | ||||||
| Property and equipment, net | 20,164 | 21,507 | ||||||
| Deferred offering costs | - | 101,205 | ||||||
| TOTAL ASSETS | $ | 82,504,659 | $ | 20,359,634 | ||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable and accrued expenses | $ | 664,533 | $ | 552,339 | ||||
| Total current liabilities | 664,533 | 552,339 | ||||||
| PPP loan payable | 108,500 | 108,500 | ||||||
| TOTAL LIABILITIES | 773,033 | 660,839 | ||||||
| COMMITMENTS AND CONTINGENCIES (NOTE 4) | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Preferred Stock - Par Value (1,000,000 authorized at March 31, 2021 and December 31, 2020; $.0001 par value) (Zero shares issued and outstanding at March 31, 2021 and December 31, 2020) | - | - | ||||||
| Common Stock - Par Value (25,000,000 authorized at March 31, 2021 and December 31, 2020; $.0001 par value) (11,181,447 shares issued and outstanding at March 31, 2021; 6,220,927 shares issued and outstanding at December 31, 2020) | 1,118 | 622 | ||||||
| Additional paid-in capital | 96,842,698 | 32,358,068 | ||||||
| Accumulated deficit | (15,112,190 | ) | (12,659,895 | ) | ||||
| Total stockholders' equity | 81,731,626 | 19,698,795 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 82,504,659 | $ | 20,359,634 |
Lantern Pharma Inc. and Subsidiary
Condensed Consolidated Statements of Operations
| Three Months Ended March 31, | ||||||||
| 2021 | 2020 | |||||||
| Operating expenses: | ||||||||
| General and administrative | 1,173,258 | 340,172 | ||||||
| Research and development | 1,279,037 | 137,104 | ||||||
| Total operating expenses | 2,452,295 | 477,276 | ||||||
| NET LOSS | $ | (2,452,295 | ) | $ | (477,276 | ) | ||
| Net loss per share of common shares, basic and diluted | $ | (0.24 | ) | $ | (0.24 | ) | ||
| Weighted-average number of common shares outstanding, basic and diluted | 10,074,623 | 2,020,966 |